[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"colon-rectal-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:colon-rectal-cancer":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,54,89],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":36,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":4},"100624165","navigation-intervention-for-adolescent-and-young-adult-cancer-survivors-100624165",false,"NCT07406087","Navigation Intervention for Adolescent and Young Adult Cancer Survivors","Adaptation and Implementation of an Evidence-Based Patient Navigation Intervention for Adolescent and Young Adult Cancer Survivors","Inclusion Criteria:\n\n* Received diagnosis of local or regional breast, ovarian, cervical, testicular, colon\u002Frectal, melanoma, endometrial, sarcoma, or thyroid cancer between the ages of 15-39 years (\"index cancer\")\n* Current age 21-45 years\n* Diagnosed and treated for index cancer within Kaiser Permanente Southern California\n* Current Kaiser Permanente insurance coverage\n\nExclusion Criteria:\n\n* Patients with a history of or current diagnosis of leukemia or lymphoma\n* Patients with metastatic disease at diagnosis","ALL","21 Years","45 Years",{"count":20,"type":21},25,"ESTIMATED","INTERVENTIONAL",[24],"NA","The investigators propose to: 1) Adapt an evidence-based cancer-focused patient navigation (PN) program for the Adolescent and Young Adult (AYA) cancer survivor population; and 2) Plan and conduct an effectiveness-implementation trial of this program within Kaiser Permanente Southern California (KPSC). PLEASE NOTE: This study is awarded in two phases. The UG3 phase has been awarded for the first two years; upon successful completion of this phase by meeting pre-defined milestones, the National Cancer Institute (NCI) will provide funding for the second phase of the study (Years 3-6), which will allow our team to conduct a trial to determine the effectiveness of the implementation of the adapted PN program for the AYA cancer survivor population. This application is focused on the initial UG3 phase and will update the protocol for the UH3 trial upon successful completion of the UG3 milestones and receipt of the UH3 award.\n\nThe primary objectives in the UG3 phase of the study are to adapt and tailor an existing PN program to meet the needs of AYA cancer survivors and the local clinical context via (a) interviews with key stakeholders (patients, clinicians, administrators) and (b) guidance from our AYA Primary Care Survivorship Council. The investigators will conduct a pilot study of the adapted PN program and refine the program to enhance acceptability to patients and clinicians, enhance feasibility and effectiveness, and develop and pilot evaluation tools and methods prior to the start of the UH3 phase of the trial, which will be a larger trial. Objectives will be updated for the UH3 phase once awarded.",[27,28,29,30,31,32,33,34,35],"Breast Cancer","Ovarian Cancer","Cervical Cancer","Testicular Cancer","Colon Rectal Cancer","Melanoma (Skin Cancer)","Endometrial Cancer","Sarcoma","Thyroid Cancer",[37,38,39,40,41],"Adolescent and Young Adult","Cancer Survivors","Patient Navigation","Adaptations","Implementation Science","NOT_YET_RECRUITING","2026-02-23",{"date":45,"type":46},"2026-02-25","ACTUAL",{"date":48,"type":21},"2026-11-01",{"date":50,"type":21},"2027-08",{"name":52,"class":53},"Kaiser Permanente","OTHER",{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":16,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":22,"phases":65,"briefSummary":67,"conditions":68,"keywords":72,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":88},"100373794","phase-1-personalized-dc-vaccine-for-postoperative-cancer-100373794","NCT04147078","Personalized DC Vaccine for Postoperative Cancer","Adjuvant Treatment in Cancer Patients with Neoantigen-primed DC Vaccine : a Single-arm, Open-label, Prospective Clinical Trial","Inclusion Criteria:\n\n* Participants with a first diagnosis of gastric cancer, hepatocellular carcinoma, non-small cell lung cancer, colorectal cancer who have undergone a curative resection or ablation\n* Anticipated life time \\> 3month\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1\n* Adequate organ functions\n\nExclusion Criteria:\n\n* Any evidence of tumor metastasis or co-existing malignant disease\n* Tumor emergency\n* Abnormal coagulation condition\n* Contagious diseases, such as hepatitis B virus, hepatitis C virus, human immunodefficiency virus, tuberculosis infection\n* Concomitant tumors\n* Immunological co-morbidities","18 Years","100 Years",{"count":64,"type":21},80,[66],"PHASE1","The study is aimed to the test efficacy and safety of neoantigen-primed dendritic cell (DC) cell vaccine therapy for postoperative locally advanced gastric cancer, hepatocellular carcinoma, lung cancer and colorectal cancer, and to explore the biomarkers related to efficacy and adverse event.",[69,70,71,31],"Gastric Cancer","Hepatocellular Carcinoma","Non-Small-Cell Lung Cancer",[73,74,75,76,77],"Cell therapy","safety","clinical efficacy","adjuvant treatment","locally advanced cancer","RECRUITING","2025-02-25",{"date":81,"type":46},"2025-02-28",{"date":83,"type":46},"2019-06-01",{"date":85,"type":21},"2026-06-01",{"name":87,"class":53},"Sichuan University",1,{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":16,"minAge":61,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":99,"phases":4,"briefSummary":100,"conditions":101,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":88},"100518298","a-study-on-the-prevalence-of-clinically-useful-mutations-in-solid-tumor-characterized-by-next-generation-sequencing-methods-on-liquid-biopsy-analysis-popcorn-100518298","NCT06028724","A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)","A Prospective, Observational Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)","POPCORN","Inclusion Criteria:\n\nPatients eligible for inclusion in this study have to meet all of the following criteria:\n\n* Patients, 18 years of age or older\n* Competent and able to comprehend, sign and date an Ethics Committee (EC) approved Informed Consent Form (ICF) before performance of any study-specific procedures or tests\n* Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures\n* Histologically proven diagnosis solid tumor\n* Diagnosis of advanced or locally advanced disease\n* Patients candidated to receive standard therapy in the following line:\n* first, second or third-line therapy for colon-rectal cancer in IV stage\n* first or second-line therapy for gastric cancer in IV stage\n* primary intent or first-line therapy for pancreatic cancer\n* first-line therapy for bile duct cancer\n* first or second-line therapy for hepatocarcinoma\n* first, second, third, fourth or fifth-line therapy for breast cancer in IV stage\n* chemotherapy for ovarian cancer in advanced stage (FIGO III-IV) and at the time of first relapse\n* first or second-line therapy for endometrial cancer in advanced stage (FIGO III-IV)\n* first or second-line therapy for advanced or locally advanced cervical cancer\n* therapy for locally advanced or first line therapy for metastatic vulva cancer\n* first, second or third-line therapy for melanoma (third-line therapy only in BRAF-mutated melanoma)\n\nExclusion Criteria:\n\n* Diagnosis of any secondary malignancy within the last 3 years, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix.\n* Patients unable or unwilling to undergo as per protocol assessments at the four planned timepoints",{"count":98,"type":21},782,"OBSERVATIONAL","The implementation of liquid biopsy in clinical practice has been favored by the rapid development of genome sequencing techniques designed to analyze mutations in ctDNA. Among these, the Next generation sequencing (NGS) is a technique that consists in sequencing several genomes in a short time span, collecting information about a wider range of genomic alterations, using small quantities of genetic material. It is used to identify potential circulating dynamic biomarkers of treatment sensitivity or resistance in a real word multi-pathology evaluation. In this way, defining the mutational status of clinical relevance genes in real world, as a predictive biomarker to identify those patients most likely to benefit from target therapy, offers the potential to optimize access to further therapies. The aim of this study is to evaluate the real-world prevalence of clinically useful mutations in patients who are receiving therapy for advanced and locally advanced solid tumor through liquid biopsy.",[102,103,104,31,69,105,106,107,27,28,33,29,108,109],"Solid Tumor","Advanced Solid Tumor","Locally Advanced Solid Tumor","Pancreatic Cancer","Bile Duct Cancer","Hepatocarcinoma","Vulva Cancer","Melanoma","2023-09-08",{"date":112,"type":46},"2023-09-13",{"date":114,"type":46},"2023-05-26",{"date":116,"type":21},"2030-05-31",{"name":118,"class":53},"Centro di Riferimento Oncologico - Aviano"]